Pfizer Inc. (NYSE:PFE) Holdings Decreased by AMG National Trust Bank

AMG National Trust Bank lessened its stake in Pfizer Inc. (NYSE:PFE) by 29.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 70,870 shares of the biopharmaceutical company’s stock after selling 30,106 shares during the period. AMG National Trust Bank’s holdings in Pfizer were worth $2,051,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Olistico Wealth LLC bought a new stake in Pfizer during the second quarter worth approximately $25,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at $29,000. Quarry LP bought a new position in Pfizer during the second quarter valued at about $31,000. Finally, Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter worth about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.3 %

Pfizer stock opened at $24.88 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company’s fifty day simple moving average is $28.55 and its 200-day simple moving average is $28.65. The stock has a market cap of $140.97 billion, a P/E ratio of 33.62, a P/E/G ratio of 0.79 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.75%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday. They issued an “underperform” rating and a $25.00 price target on the stock. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Finally, UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.